Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimavanserin Tartrate

FDA-approved product (tablet, oral), marketed as Nuplazid, Pimavanserin.

Registered studies
46
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pimavanserin Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hallucinations
  • Parkinson disease
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimavanserin Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimavanserin Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

    NCT03118947 · start 2017-02-23

    Registered record
    Registry ID
    NCT03118947
    Conditions
    Agitation and Aggression in Alzheimer's Disease
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-02-23
    Completion
    2019-02-25
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation and Aggression in Alzheimer's Disease
    InterventionPimavanserin
    PhasePhase 2
    Registry statusCompleted

  • Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

    NCT03121586 · start 2017-01

    Registered record
    Registry ID
    NCT03121586
    Conditions
    Schizophrenia
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-01
    Completion
    2024-05-30
    Enrolment
    995

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPimavanserin
    PhasePhase 3
    Registry statusTerminated

  • Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

    NCT03018340 · start 2016-12

    Registered record
    Registry ID
    NCT03018340
    Conditions
    Adjunctive Treatment of Major Depressive Disorder
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12
    Completion
    2018-10
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdjunctive Treatment of Major Depressive Disorder
    InterventionPimavanserin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

    NCT02970305 · start 2016-11-04

    Registered record
    Registry ID
    NCT02970305
    Conditions
    Schizophrenia
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11-04
    Completion
    2019-10-28
    Enrolment
    403

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPimavanserin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

    NCT02992132 · start 2016-11

    Registered record
    Registry ID
    NCT02992132
    Conditions
    Agitation and Aggression in Alzheimer's Disease
    Interventions
    Pimavanserin 34 mg; Pimavanserin 20 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-11
    Completion
    2018-02-16
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation and Aggression in Alzheimer's Disease
    InterventionPimavanserin 34 mg; Pimavanserin 20 mg; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

    NCT02970292 · start 2016-10-26

    Registered record
    Registry ID
    NCT02970292
    Conditions
    Schizophrenia
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10-26
    Completion
    2019-06-25
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPimavanserin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

    NCT02035553 · start 2013-11

    Registered record
    Registry ID
    NCT02035553
    Conditions
    Alzheimer's Disease Psychosis
    Interventions
    Pimavanserin tartrate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-11
    Completion
    2016-10-27
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease Psychosis
    InterventionPimavanserin tartrate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

    NCT01174004 · start 2010-07

    Registered record
    Registry ID
    NCT01174004
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    pimavanserin tartrate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-11
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    Interventionpimavanserin tartrate; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    NCT00658567 · start 2008-03

    Registered record
    Registry ID
    NCT00658567
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    Pimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-12
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    InterventionPimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103)
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    NCT00550238 · start 2007-07

    Registered record
    Registry ID
    NCT00550238
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    Pimavanserin tartrate (ACP-103)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2018-05-30
    Enrolment
    459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    InterventionPimavanserin tartrate (ACP-103)
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    NCT00477672 · start 2007-06

    Registered record
    Registry ID
    NCT00477672
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    Pimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-07
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    InterventionPimavanserin tartrate (ACP-103); Pimavanserin tartrate (ACP-103); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

    NCT00361166 · start 2005-08

    Registered record
    Registry ID
    NCT00361166
    Conditions
    Schizophrenia
    Interventions
    ACP-103
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2007-03
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionACP-103
    PhasePhase 2
    Registry statusCompleted

  • An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

    NCT01518309 · start 2004-11-17

    Registered record
    Registry ID
    NCT01518309
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    pimavanserin tartrate (ACP-103)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-11-17
    Completion
    2013-05-02
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    Interventionpimavanserin tartrate (ACP-103)
    PhasePhase 2
    Registry statusCompleted

  • ACP-103 to Treat Parkinson's Disease

    NCT00086294 · start 2004-06-25

    Registered record
    Registry ID
    NCT00086294
    Conditions
    Parkinson's Disease; Dyskinesias
    Interventions
    Intravenous Levodopa; ACP-103
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-06-25
    Completion
    2007-11-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Dyskinesias
    InterventionIntravenous Levodopa; ACP-103
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

    NCT00087542 · start 2004-03

    Registered record
    Registry ID
    NCT00087542
    Conditions
    Hallucinations; Psychoses; Parkinson's Disease
    Interventions
    ACP-103
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2005-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHallucinations; Psychoses; Parkinson's Disease
    InterventionACP-103
    PhasePhase 2
    Registry statusCompleted